FDA Slaps Warning Label On Certain Puberty-Blocking Drugs

Over the past year-and-a-half, the Biden administration has made its support for medical treatments that affirm the “transgender” identities of children and youth—as well as its support for the rest of the “transgender” agenda—abundantly clear. Assistant Health Secretary Rachel Levine, a biological male who identifies as “transgender,” has described such medical treatments (misleadingly referred to as “gender-affirming care”) as “‘life-saving’” and “‘medically necessary.’” But are these treatments really safe and healthy for kids?

In July 2022, the U.S. Food and Drug Administration (FDA) placed a warning label on a certain type of puberty blockers known as “‘gonadotropin-releasing hormone (GnRH) substances.’” Puberty blockers are used to delay puberty in children that experience precocious puberty; however, they are also used to prevent children who identify as “transgender” from experiencing normal puberty and developing appropriate secondary sex characteristics. According to DailySignal.com, the FDA took this action because six minors developed severe brain-related symptoms after taking GnRH substances. The children reportedly experienced pseudotumor cerebri, in which increased pressure inside the brain leads to symptoms that mimic brain tumor symptoms. Such symptoms include eye paralysis, headache, vomiting, optic nerve swelling, and vision disturbances in which patients see lights that do not exist.

Jennifer Bauwens of Family Research Council commented that “‘[we] already have studies showing the negative effects of both puberty blockers and cross-sex hormones.’” However, Bauwens acknowledged that “‘any time we see more evidence and more publicity on the damage that these drugs do to kids, it’s helpful.’”

New Yorkers for Constitutional Freedoms calls upon the Biden administration to cease its pro-LGBT misinformation campaign about so-called gender-affirming care for minors.